SAN DIEGO, Nov. 1, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and nine months ended September 30, 2011. Revenues were $26.6 million for the third quarter of 2011 compared with $2.3 million for the third quarter of 2010, primarily as a result of the recognition of $25.1 million of license revenue for TransVax™, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
